Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIIb study of HPV-16/18 AS04 vaccine in healthy females aged 10-25 years
2017-000416-42Phase 3
- Sponsor
- GSK
- Start
- Sep 2017
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of HPV-16/18 L1 AS04 vaccine in human papillomavirus infection, Cervical Cancer (CC), Vulval carcinoma and 4 more (2 arms), sponsored by GSK. Primary endpoint: Seroconversion for anti-HPV-16 and anti-HPV-18 antibodies.
02
Drugs
HPV-16/18 L1 AS04 vaccine
03
Conditions
human papillomavirus infectionCervical Cancer (CC)Vulval carcinomavaginal cancercervical intraepithelial neoplasia (CIN)
Beyond the preview
Go deeper on 2017-000416-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000416-42.